ArticleThe Pediatric infectious disease journal2026
Body Mass Index and Vaccine-induced Immune Responses in Children Living With HIV.
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundChildren living with HIV are experiencing rising rates of obesity, driven by both the side effects of antiretroviral therapy and the increasingly obesogenic environments. Obesity and HIV are both known to cause immune dysregulation, which may have a combined negative effect on vaccine-induced immune response in this vulnerable population. This study aimed to determine whether body mass index z-score (BMIz) is associated with vaccine-induced antibody concentrations in children living with HIV.
methodsThis study used data from clinical trials for 3 separate vaccines (hepatitis A, hepatitis B and pneumococcal [conjugate plus polysaccharide]) administered to children living with HIV. Enrollment was between September 1999 and March 2003 in the United States. Adjusted linear regression for interval-censored data and logistic regression models were used to assess associations for BMIz with antibody response up to 104 weeks after vaccine administration.
resultsParticipant age ranged from 2 to 20 years old. Analyses included 150 participants for the hepatitis A vaccine, 154 for the hepatitis B vaccine and 214 for the pneumococcal vaccine. BMIz was associated with hepatitis B antibody concentration 8 weeks after vaccination ( P = 0.026) with the highest probability (47%) of seroconversion for participants with BMIz near 1. There was no statistically significant association between BMIz and antibody response for the hepatitis A vaccine or 4 of 5 studied serotypes in the pneumococcal vaccine (n = 214).
conclusionsThe hepatitis A, hepatitis B and pneumococcal vaccines are likely adequate as administered and protective for children living with HIV at a broad range of BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.